Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Jianming Xu(Chinese PLA General Hospital), Ken Kato(Tokyo National Hospital), Eric Raymond(Hôpital Paris Saint-Joseph), Richard Hubner(University of Manchester), Yongqian Shu(Jiangsu Province Hospital), Yueyin Pan(Anhui Provincial Hospital), Sook Ryun Park(University of Ulsan), Lu Ping(Xinxiang Medical University), Yi Jiang(Shantou University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Xiaohong Wu(Wuxi Fourth People's Hospital), Yuanhu Yao(Xuzhou Medical College), Lin Shen(Peking University Cancer Hospital), Takashi Kojima(National Cancer Center Hospital East), Evgeny Gotovkin, Ryu Ishihara(Osaka International Cancer Institute), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Eric Van Cutsem(KU Leuven), Paula Jiménez‐Fonseca(Hospital Universitario Central de Asturias), Chen‐Yuan Lin(China Medical University Hospital), Lei Wang(BeiGene (China)), Jingwen Shi(BeiGene (China)), Liyun Li(BeiGene (China)), Harry H. Yoon(Mayo Clinic in Arizona)
Cited by 285